D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times F.B. Spencker, L. Staber, T. Lietz,

Rapid streptococcal testing for sore throat and antibiotic resistance

Intravenous antibiotics given for 2 weeks do not eradicate persistent Staphylococcus aureus clones in cystic fibrosis patients C. Andersen, B.C. Kahl,

Thirty-day mortality of nosocomial systemic bacterial infections according to antibiotic susceptibility in an 800-bed teaching hospital in France D.

Sputum colour reported by patients is not a reliable marker of the presence of bacteria in acute exacerbations of chronic obstructive pulmonary disease

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients R. Cantón, N. Cobos,

Gut bacterial microbiota and obesity

Salvage therapy for multidrug-resistant tuberculosis

Infections in Patients with Cystic Fibrosis

Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones J. Mensa, A. Trilla

A. M. M. de Vrankrijker, C. K. van der Ent, F. T. van Berkhout, R. K

Migrant health—a cause for concern?

E. Bronska, J. Kalmusova, O. Dzupova, V. Maresova, P. Kriz, J. Benes

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

William G. Flight, Jonathan Shaw, Susan Johnson, A

Inhaled antibiotic therapy: What drug. What dose. What regimen

R. Cantón Clinical Microbiology and Infection

Lactate in cystic fibrosis sputum

Rapid streptococcal testing for sore throat and antibiotic resistance

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics

Non-antibiotic strategies for sepsis

P. Davey, C. Pagliari, A. Hayes Clinical Microbiology and Infection

Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection

Surveillance of Legionnaires’ disease in Austria

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Vector control: a cornerstone in the malaria elimination campaign

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

A. Oliver, A. Mena Clinical Microbiology and Infection

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

G. Höffken Clinical Microbiology and Infection

Does it make sense to detect Streptococcus pyogenes during tonsillitis in Europe to prevent acute rheumatic fever? S. Edouard, A. Michel-Lepage, D. Raoult

F. Bittar, J.-M. Rolain Clinical Microbiology and Infection

Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium M. Denton, M.J. Hall, N.J.

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients J.L. Fothergill,

Salvage therapy for multidrug-resistant tuberculosis

The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples G.B. Rogers, P. Marsh, A.F. Stressmann, C.E. Allen,

Elements of design: the knowledge on which we build

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

M. C. Alanin, K. G. Nielsen, C. von Buchwald, M. Skov, K. Aanaes, N

Detection of, and frequent co-infection with, human bocavirus in faecal specimens from children in Wuhan, China Y. Huang, P. Mao, H. Wang Clinical Microbiology.

Recent developments in staphylococcal scalded skin syndrome

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Systematic review of antibiotic consumption in acute care hospitals

Pandemic lineages of extraintestinal pathogenic Escherichia coli

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

Statin use and clinical outcomes among pneumonia patients

P. Kaltsas, S. Want, J. Cohen Clinical Microbiology and Infection

Clinical Microbiology and Infection

W. Eugene Sanders, Christine C. Sanders

Tuberculosis in HIV-infected patients: a comprehensive review

Carratalà J. Clinical Microbiology and Infection

B.A. Cunha Clinical Microbiology and Infection

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Community-acquired acute bacterial meningitis in the elderly in Turkey

Impact of antibiotic restrictions: the patient's perspective

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P

Abstracts Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M. Borneff-Lipp, G. Döring Clinical Microbiology and Infection Volume 15, Issue 5, Pages 454-460 (May 2009) DOI: 10.1111/j.1469-0691.2008.02659.x Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Equivalence of facultative and obligate anaerobic bacterial cell numbers in respiratory specimens of cystic fibrosis (CF) patients. Cell numbers of facultative and obligate anaerobes were evaluated in 41 sputum samples and seven throat swabs obtained from CF patients. Clinical Microbiology and Infection 2009 15, 454-460DOI: (10.1111/j.1469-0691.2008.02659.x) Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 Antibiotic therapy for acute exacerbations does not influence sputum cell numbers of facultative and obligate anaerobic bacteria, but does lead to an increase in lung function. Sputum bacterial counts of facultative and obligate anaerobes (a), forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) (b) in 12 cystic fibrosis patients suffering from acute exacerbations before (▪) and after (□) intravenous Pseudomonas aeruginosa-specific antibiotic therapy. Clinical Microbiology and Infection 2009 15, 454-460DOI: (10.1111/j.1469-0691.2008.02659.x) Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions